

Yang, H., Ye, D., Guan, K., & Xiong, Y. (2012). IDH1 and IDH2 Mutations in Transgenic: Mechanistic Insights and Clinical Perspectives. *Clinical Cancer Research*, 18(20), 5562-5571. doi:10.1158/1078-0432.ccr-12-1773

Vokocher W. Constitutive SNK1AK/STAT signaling in hematological malignancies. *Oncogene* (2013);32:2601-2613. doi:10.1038/ncr.2012-247

Balsani, J., Morales, M. R., Cao, S., & Hagan, J. P. (2017). The LIN28/67 Pathway in Cancer. *Frontiers in Genetics*, 8, 31. <https://doi.org/10.3389/fgene.2017.00031>

Barone, G., Veldick, D., Shofst, J., Chevalier, L., Moreno, L., Pearson, A., & Markovits, T. (2014). MDM2/p53 Interaction in Pediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. *Current Drug Targets*, 15(11), 114-123. doi:10.2174/15748848111149990194

Ciocarelli, C., Vekano, F., Milazzo, L., Gravina, G. L., Marampio, F., Marice, G., ... Zani, R. M. (2016). Key role of MEK/ERK pathway in sustaining immunogenicity and *in vitro* radiosensitivity of epithelial rhudomyosarcoma stem-like cell population. *Molecular Cancer*, 15(1), doi:10.1186/s12943-016-0500-y

Slany, R. K. (2016). The molecular mechanics of mixed lineage leukemia. *Oncogene*, 35(40), 5215-5223. doi:10.1038/ncr.2016-50

Beutler, E. (2007). Faculty of 1000 evaluation for Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumours: A report from the Children's Oncology Group. F1000. First publication Peer Review of the BioMed Central Literature doi:10.54107/1098180.554184

Winters, A. C., & Bent, K. M. (2017). MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches. *Frontiers in Pediatrics*, 5, doi:10.3389/fped.2017.00006

Barrett, D., Brown, V. L., Grigg, S. A., & Teachey, D. T. (2012). Targeting the PI3K-Akt/mTOR Signaling Axis in Children with Hematologic Malignancies. *Pediatric Drugs*, 14(5), 299-316. doi:10.1007/s00262026256

Harter, S., Bohn, S., Weisburger, H., & Swartling, F. (2017). Modeling and Targeting MYC Genes in Childhood Brain Tumors. *Genes*, 8(4), 107. doi:10.3390/genes8040107

Sak, A. (2015). Editorial: Targeting MYC in Pediatric Cancers. *Frontiers in Oncology*, 4, doi:10.3389/fonc.2014.00330

Schumacher, T. N., & Schreiber, R. D. (2015). Neointens in cancer immunotherapy. *Science*, 348(6290), 69-74. doi:10.1126/science.1260971

Cahill, K. E., Morabito, R. A., & Yamin, B. (2015). Nuclear factor-κB in glioblastoma: Insights into regulators and targeted therapy. *Neuro-Oncology*, 16(3), 525-539. doi:10.1093/neuonc/nou265

Zapp, P. E., Noh, K., Fang, W., Stewart, J., Garcia-Manero, G., & Zander-McKay, P. A. (2011). Notch pathway activation induces neuroblastoma tumor cell growth arrest. *Pediatric Blood & Cancer*, 56(5), 682-689. doi:10.1002/pbc.21202

French, C. A., Rahman, S., Walsh, M. M., Kibula, S., Grayson, A. R., Lessner, M. E., ... Hoxley, P. M. (2014). NDS1/NTF Fusion Oncoprotein in NTF Mediated Carcinoma: Implications for a Novel Oncogenic Mechanism. *Cancer Discovery*, 4(6), 928-941.

Meyer, J. A., Wang, J., Hojani, L. E., Yang, J. J., Dandekar, S., Patel, J. P., ... Carroll, W. L. (2013). Reciprocal specific mutations in NTS2C1 in childhood acute lymphoblastic leukemia. *Nature Genetics*, 45(3), 290-294. <https://doi.org/10.1038/ng.2558>

Prasad, M. L., Vyas, M., Hoss, M. J., Vek, R. K., Mironi, R., Liu, Z., ... Nikiforov, Y. E. (2016). NTRK3 fusion oncogenes in pediatric pituitary thyroid carcinoma in northeast United States. *Cancer*, 122(7), 1097-1107. doi:10.1002/cncr.29807

Schultz, C. R., Green, D., Mooney, M., El-Khawaja, R., Kowal, J., & Bachmann, A. S. (2018). Synergistic drug combination GCT-103903 suppresses hypoxia/serum-deprived eIF5A activation and induces apoptotic cell death in neuroblastoma. *Biochemical Journal*, 475(2), 531-545. doi:10.1042/bj0750097

Rick, T. K., Chin, H. J., Fong, G., Kim, G., McKee, A. E., Kherif, P., & Fardip, R. (2015). Successes and Challenges of PARP Inhibitors in Cancer Therapy. *Frontiers in Oncology*, 5, 222. <https://doi.org/10.3389/fonc.2015.00222>

Linares, C. M. (2008). PAX3-FOXO1 fusion gene in rhabdomyosarcoma. *Cancer Letters*, 270(1), 10-18. doi:10.1016/j.canlet.2008.03.035

Heldin, C. (2013). Targeting the PDGF signaling pathway in tumor treatment. *Cell Communication and Signaling*, 11(1), 97. doi:10.1186/1747-1028-11-97

Khan, K. H., Vay, T. A., Yau, L., & Campling, D. (2013). Targeting the PI3K-Akt-mTOR signaling network in cancer. *Chinese Journal of Cancer*, 12(5), 253-265. doi:10.5717/cjc.013.10057

Kenny, M. A., et al. (2019). "Outcomes for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance)." *Pediatric Blood Cancer* 66(5): 675-674. <https://doi.org/10.1002/pbc.25750>

Milosevic, J., Eskola, N., Treks, D., Wikstrom, M., Fransson, S., Svehlichmanova, R., ... Kogut, P. (2017). Abnorn 1945: PPM1D(Wp1), promising new target in childhood cancers neuroblastoma and neuroblastoma. *Cancer Research*, 77(13) Supplement, 1945-1945. doi:10.1158/1538-7445.ccr17-1945

Ward, A. F., Braun, B. S., & Shannon, K. M. (2012). Targeting oncogenic Ras signaling in hematologic malignancies. *Blood*, 120(17), 3397-3406. doi:10.1182/blood-2012-05-378796

Lavy, A. S., Roth, M., Patterson, N., Scott, E., Oshiro-Tanaka, W., Ewari, M. R., ... Montagna, C. (2016). Abstract 15: Target next sequencing profiling of pediatric solid tumors: Potential use for the identification of actionable mutations. *Clinical Cancer Research*, 22(1) Supplement, 15-15. doi:10.1158/1557-3265.pccr15-1515

Perez-Garcia, A., Amador-Improbato, A., Huelter, M., Riggs, I., LeDuc, C. A., Kelly, K., ... Ferrando, A. A. (2013). Genetic loss of SH2B1 in acute lymphoblastic leukemia. *Blood*, 122(14), 2425-2432. <https://doi.org/10.1182/blood-2013-05-505800>

Liu, X., Zheng, H., Li, X., Wang, S., Meyerson, H. J., Yang, W., ... Ou, C.-K. (2016). Gain-of-function mutation of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage induced malignancies. *Proceedings of the National Academy of Sciences of the United States of America*, 113(4), 984-989. <https://doi.org/10.1073/pnas.1508551113>

Rinkus, T., Carpenter, R., Quisen, S., Chan, M., & Lo, H. (2016). Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and G1 Inhibitors. *Cancers*, 8(2), 32. doi:10.3390/cancers8020032

The Cancer Genome Atlas Research Network. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *The New England Journal of Medicine*, 2015;372(26):2481-2498. doi:10.1056/NEJMoa1402121. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4250011/>

Mullighan CG, Collins-Underwood JR, Phillips LA, et al. REARRANGEMENT OF CRLF2 IN B-PROGENITOR AND T-DOWNS SYNDROME ASSOCIATED ACUTE LYMPHOBLASTIC LEUKEMIA. *Nature genetics*. 2009;41(11):1243-1246. doi:10.1038/ng.469. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC278383/>

Grothm, A. V., Vigh, N., Moreno-Suñth, M., Vandevas, S. A., Harbort, E., Spreitzer, M., ... Mierkes, T. V. (2017). Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma. *Oncotarget*, 8(34), doi:10.18632/oncotarget.11992

Liu, H., Cheng, E. H., & Hoish, J. J. (2009). MLL fusions: Pathways to leukemia. *Cancer Biology & Therapy*, 10(13), 1208-1211. <https://doi.org/10.4161/cbt.101309>

Grout M, Shalby T. MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges. *Current Cancer Drug Targets* (2016); 1:2-21. Department of Oncology, University Children's Hospital Zurich, Switzerland. doi: 10.2174/156800961566150916092745. <http://www.warwick.ac.uk/go/134984>

Campbell BB, Light N, Fabrizio D, et al. Comprehensive Analysis of Hypomethylation in Human Cancer Cells. 2017;17(1):51-1042-1056.e10. doi:10.1016/j.ccr.2017.09.048. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC543939/>

Ferrando, A. A. (2009). The role of NOTCH1 signaling in T-ALL. *Hematology*, 2009(1), 353-361. doi:10.1182/haematol.2009.1353

Additional References: Please click the URL -> >>>>>>>

DeRo, A., Luetch, T.W.I., Kumar, S.I., DaSilva, S.G.I., Lassen, U.N.I., Demeri, G.D.I., Nishimura, M.I., Duester, R.C.I., Fungo, A.F.I., Dappa, A.S.I., Tuma, B.I., Davelos, A.I., Rose, M.S.I., Maccorubbi, L.I., Federman, N.I., Berlin, J.I., El-Dary, W.S.I., Bak, C.I., Decken, J.I., Boni, V.I., Nagaphaniraman, K.I., Taylor, M.I., Rastogi, E.R.I., Merz, Berman, F.I., Sahai, D.P.S.I., Ma, P.C.I., Razi, J.E.I., Hochman, J.F.I., Rosnyed, R.I., Ladanyi, M.I., Tsch, B.H.I., Ebara, K.I., Coudachon, S.I., Rio, N.C.I., Cox, M.C.I., Hawkins, D.S.I., Hong, D.S.I., Hyman, D.M.I. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med*. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoA1714488. <https://www.nature.com/articles/d41261f>

Lo-Coco, F., et al. (2013). "Retinoic acid and arsenic trioxide in acute promyelocytic leukemia." *N Engl J Med* 369(2): 111-121. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC350297/>

Tillman, G.S. and J. K. Altman (2009). "How to cure acute promyelocytic leukemia." *Blood* 113(5): 2405-2415. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749019/>

Wang, Z. Y., and Z. Chen (2008). "Acute promyelocytic leukemia: from highly fatal to highly curable." *Blood* 111(5): 2405-2415. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749019/>

Platzbecker, U., et al. (2017). "Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial." *J Clin Oncol* 35(6): 605-612. <https://doi.org/10.1200/JCO.2016.34.8293>

Tillman, G.S. and J. K. Altman (2009). "How to cure acute promyelocytic leukemia." *Blood* 113(5): 2405-2415. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749019/>

Wang, Z. Y., and Z. Chen (2008). "Acute promyelocytic leukemia: from highly fatal to highly curable." *Blood* 111(5): 2405-2415. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749019/>

STAT2L3	STAT2L3	Yue, C., Xu, J., Estéola, M. D. T., Korredes, K. P., Lopez-Olabona, Y., Hilliard, B. A., ... Gammels, A. M. (2015). Host STAT2/type I interferon axis controls tumor growth. <i>International Journal of Cancer. Journal International Du Cancer</i> , 136(1), 117-126. http://dx.doi.org/10.1002/ijc.29054 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199898/	
SYT-SSX	SYT-SSX	Seguinier, S., Leschner, I., Poteraba, C., Ladenslein, R., Kazanowska, B., Jungmann, G., ... Kowtschuk, E. (2016). The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS Cooperative Weichteilneoplasien Study trial. <i>Pediatric Blood & Cancer</i> , 64(1), 89-95. doi:10.1002/pbc.26206 https://www.ncbi.nlm.nih.gov/pubmed/27621863	
TERT	TERT	Rehman, Z. J., Pirozzi, C. J., & Yan, H. (2013). Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. <i>Acta Neuropathologica</i> , 126(6), 789-792. http://dx.doi.org/10.1007/s00401-013-1207-5 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888613/	
TORC1/2 as distinct from mTOR	TORC1/2	Foster, K. G., & Fingar, D. C. (2010). Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony. <i>Journal of Biological Chemistry</i> , 285(19), 14071-14077. doi:10.1074/jbc.109.096003 http://www.jbc.org/content/285/19/14071.full	
TMB	TMB	Annis, A., Sartore-Bianchi, A., & Siena, S. (2016). NTRK gene fusion as novel targets of cancer therapy across multiple tumor types. <i>ESMO Open</i> , 1(2), e000023. http://dx.doi.org/10.1136/esmoopen-2015-000023 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070277/	Liang, AM, Lo H-W. Inhibiting TRK Proteins in Clinical Cancer Therapy. <i>Cancers</i> . 2018;10(4):105. doi:10.3390/cancers10040105. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923940/
TP53	TP53	Rausch, T., James, D., Zappavigna, M., Stone, A., Zehner, E., Weischenfeldt, J., ... Korbel, J. (2012). Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. <i>Cell</i> , 148(1-2), 99-111. doi:10.1016/j.cell.2011.12.013 https://www.ncbi.nlm.nih.gov/pubmed/2265462	
TYK2	TYK2	Wanders, E., Schrijn, B., Jongmans, M. C., Vozzelaar, H., Reijnen, S. V., Dijk, A. H., ... Kuiper, R. P. (2016). Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences. <i>Leukemia</i> , 31(6), 821-828. doi:10.1038/leu.2016.277 https://www.nature.com/articles/leu2016277	
ZNF512-NUTM1	ZNF512-NUTM1	French CA, Kosik JL, Fagin WC, Totonóky JA, Antonescu CR, Griffin CA, Nave V, Vargiu SO, Mochkov M, Tsirintanis-Nathopoulos F, Miyoshi H, Perez-Ayala AR, Aster JC, Fletcher JA. Maflike carcinoma of children and young adults with NUT rearrangement. <i>J Clin Oncol</i> . 2004;22:20-4155-9. https://www.ncbi.nlm.nih.gov/pubmed/14483021 file:///C:/Users/Akshaygubhu/Downloads/BN_French_2018_PedMolCellJTarget.htm	

Additional References: Please click the URL. →→→→→→→→→→

1

ERBB2 (HER2/Neu)	Orentas, R. J., Lee, D. W., & Mackall, C. (2012). Immunotherapy Targets in Pediatric Cancer. <i>Frontiers in Oncology</i> , 2, 3. http://doi.org/10.3389/fonc.2012.00003	Gilbertson, R. J. (2005). ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty. <i>The Oncologist</i> , 10(7), 508-517. doi:10.1634/theoncologist.10-7-508	http://theoncologist.alphamedpress.org/content/10/7/508.full	
IL6	Egler, R. A., Burlingame, S. M., Nuchtern, J. G., & Russell, H. V. (2008). Interleukin-6 and soluble IL-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. <i>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</i> , 14(21), 7028-7034. http://doi.org/10.1158/1078-0432.CCR-07-5017	Stevens AM, Miller JM, Munoz JO, Gaiwad AS, Redell MS. Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. <i>Blood Advances</i> . 2017;1(8):1387-1397. doi:10.1182/bloodadvances.2017007856.	https://www.ncbi.nlm.nih.gov/pubmed/29173755/	
IL13RA2	Deng, H., Zeng, J., Zhang, T., Gong, L., Zhang, H., Cheung, E., ... Li, G. (2018). Histone H3.3K27M Mobilizes Multiple Cancer/Tests (CT) Antigens in Pediatric Glioma. <i>Molecular Cancer Research</i> , 16(4), 623-633. doi:10.1158/1541-7786.mcr-17-0460	http://mcr.aacrjournals.org/content/16/4/623		
LRRCL15	Reynolds PA, Smolen GA, Palmer RE, et al. Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+K15) oncoprotein. <i>Genes & Development</i> . 2003;17(17):2094-2107. doi:10.1101/gad.1110703	https://www.ncbi.nlm.nih.gov/pubmed/1264592/		
MAGE-A3	Jacobs, J. F., Brasseur, F., Kas, C. A., Rakt, M. W., Figdor, C. G., Adema, G. J., ... Vries, I. J. (2006). Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. <i>International Journal of Cancer</i> , 120(1), 67-74. doi:10.1002/ijc.22118	Lee AK, Potts PR. A comprehensive guide to the MAGE family of ubiquitin ligases. <i>Journal of molecular biology</i> . 2017;429(8):1114-1142. doi:10.1016/j.jmb.2017.03.005.	https://www.ncbi.nlm.nih.gov/pubmed/28154671/	
MSLN (mesothelin)	Steinbach, D. (2006). Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 12(8), 2434-2441. doi:10.1158/1078-0432.ccr-05-2552	http://clincancerres.aacrjournals.org/content/12/8/2434.full.pdf		
NR5A1 (Steroidogenic factor-1)	Ferraz-de-Sousa, B., Lin, L., & Achermann, J. C. (2011). Steroidogenic factor-1 (SF-1, NR5A1) and human disease. <i>Molecular and Cellular Endocrinology</i> , 336(1-2), 198-205. http://doi.org/10.1016/j.mce.2010.11.006	https://www.ncbi.nlm.nih.gov/pubmed/2057017/		
NY-ESO-1	Singh, N., Kulkovskaya, I., Barent, D. M., Binder-Scholl, G., Jakobsen, B., Martinez, D., ... Grupp, S. A. (2016). T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. <i>Oncotarget</i> , 7(1), e1040216. http://doi.org/10.1080/2162402X.2015.1040216	https://www.ncbi.nlm.nih.gov/pubmed/26503644/		
Olig2	Kapp, R., Shayer, L., Ten, A.-C., Sotelo, E., Sami, N., Rowitch, D. H., & Mehta, S. (2016). Language-restricted Olig2: RTK signaling governs the molecular subtype of glioma stem-like cells. <i>Cell Reports</i> , 16(11), 2838-2845. http://doi.org/10.1016/j.celrep.2016.08.040	https://www.ncbi.nlm.nih.gov/pubmed/2742711/		
PIK3CD (PI3 kinase delta)	Khan, K. H., Yag, T. A., Yan, L., & Cunningham, D. (2013). Targeting the PI3K-AKT-mTOR signaling network in cancer. <i>Chinese Journal of Cancer</i> , 32(5), 253-265. doi:10.5732/cjc.013.10057	https://www.ncbi.nlm.nih.gov/pubmed/24339415/		
PRAME	Oberthuer, A. (2004). The Tumor-Associated Antigen PRAME Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome. <i>Clinical Cancer Research</i> , 10(13), 4307-4313. doi:10.1158/1078-0432.ccr-03-0813	Khatieb EE, Morgan D. Preferentially Expressed Antigen of Melanoma (PRAME) and Wilms' Tumor 1 (WT1) Genes Expression in Childhood Acute Lymphoblastic Leukemia, Prognostic Role and Correlation with Survival. <i>Open Access Macedonian Journal of Medical Sciences</i> . 2015;3(1):57-62. doi:10.3889/oajmms.2015.001.	https://www.ncbi.nlm.nih.gov/pubmed/15240516/	https://www.ncbi.nlm.nih.gov/pubmed/26177789/
PTEN	Zaubier, L., Petricoin, E. F., Vuerhard, M. J., Calvert, V., Kooi, C., Buji-Gladdines, J. G. C. A. M., ... Mejerink, J. P. P. (2012). The significance of PTEN and AKT1 aberrations in pediatric T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 97(9), 1405-1413. http://doi.org/10.3324/haematol.2011.059030	https://www.ncbi.nlm.nih.gov/pubmed/22436243/		
SYK	Cain, C. (2012). SYK inhibitors on retinoblastoma. <i>Science-Business Exchange</i> , 5(7). doi:10.1038/scsbx.2012.168	Saletta F, Wadham C, Ziegler DS, et al. Molecular profiling of childhood cancer: Biomarkers and novel therapies. <i>BBA Clinical</i> . 2014;1:59-77. doi:10.1016/j.bbacc.2014.06.003.	https://www.ncbi.nlm.nih.gov/pubmed/23136138/	https://www.ncbi.nlm.nih.gov/pubmed/24633945/
WT1	Noronha, S. A., Farrar, J. E., Alonzo, T. A., Gerbing, R. B., Lacayo, N. J., Dahl, G. V., ... Loeb, D. M. (2009). WT1 expression at diagnosis does not predict survival in pediatric AML: A report from the Children's Oncology Group. <i>Pediatric Blood & Cancer</i> , 53(6), 1136-1139. http://doi.org/10.1002/pbc.22142	Masseret C, Liu Q, Nguyen E, et al. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non MYCN amplified neuroblastoma. <i>Molecular Oncology</i> . 2016;10(2):240-252. doi:10.1016/j.molonc.2015.09.010.	https://www.ncbi.nlm.nih.gov/pubmed/19292613/	https://www.ncbi.nlm.nih.gov/pubmed/27154671/
YAP1	Abduch, R. H., Bueno, A. C., Leal, L. F., Cavalcanti, M. M., Gomes, D. C., Brandalise, S. R., ... Antonini, S. R. (2018). Unravelling the expression of the oncogene YAP1, a Wnt/beta-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients. <i>Oncotarget</i> , 7(51), 84634-84644. http://doi.org/10.18632/oncotarget.12382	https://www.ncbi.nlm.nih.gov/pubmed/30366887/	Rampal R, Figueroa ME. Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. <i>Haematologica</i> . 2016;101(6):672-679. doi:10.3324/haematol.2015.141796.	https://www.ncbi.nlm.nih.gov/pubmed/27154671/

Tumor MicroENVT&Immu noTherapy Target

Symbol	Citation(1)	Link(1)	Citation(2)	Link(2)	Citation(3)	Link(3)	Comments
B7H3	Theruvath J, Heitzenseder S, Majzner R, Cui K, Nellan A, Graef C, M... . Mitra S. S. (2017). Immune-45 Checkpoint Molecule B7-H3 Is Highly Expressed On Medulloblastoma And Proves To Be A Promising Candidate For Car T Cell Immunotherapy. Neuro-Oncology, 19(Suppl_6), vi123-1122. doi:10.1093/neuonc/nwx168.503	https://academic.oup.com/neuro-oncology/article-abstract/19/suppl_6/vi123/4599331?redirectedFrom=ultrixt	Yafian M, Yari F, Ghannazadeh M, Fallah Azad V, Haghjoo M. Induction of Apoptosis in Cancer Cells of pre-B ALL Patients after Exposure to Platelets, Platelet-Derived Microparticles and Soluble CD40 Ligand. Cell Journal (Yakhteh). 2018;20(1):130-136. doi:10.22074/cellj.2018.5032.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799674/			
CD40	Petrov I, Sutsyova M, Matorova O, et al. Molecular pathway activation features of pediatric acute myeloid leukemia (AML) and acute lymphoblast leukemia (ALL) cells. Aging (Albany NY). 2016;8(11):2936-2946. doi:10.18632/aging.101102.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5182073/	Vonderheide, R. H. (2007). Prospect of Targeting the CD40 Pathway for Cancer Therapy. Clinical Cancer Research, 13(4), 1083-1088. doi:10.1158/1078-0432.ccr-06-1893	http://clincancerres.aacrjournals.org/content/13/4/1083			
CD47	An Anti-CD47 Antibody Is Effective in Pediatric Brain Tumor Models. (2017). Cancer Discovery, 7(5). doi:10.1158/2159-8290.cd-rw.2017-057	http://cancerdiscovery.aacrjournals.org/content/7/5/453.2.full-text.pdf					
CD52	Angiolillo, A. L., Yu, A. L., Reaman, G., Ingle, A. M., Secola, R., & Adamson, P. C. (2009). A Phase II Study of Campath-1H in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Pediatric Blood & Cancer, 53(6), 978-983. http://doi.org/10.1002/pbc.22209	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120889/					
CXCR4	Matsuo, H., Nakamura, N., Tomizawa, D., Saito, A. M., Kiyokawa, N., Horibe, K., . . . Adachi, S. (2016). CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatric Blood & Cancer, 63(8), 1394-1399. doi:10.1002/pbc.26035	https://www.ncbi.nlm.nih.gov/pubmed/27135782					
CXCL10	Flores-RJ, Kelly AJ, Li Y, et al. A Novel Prognostic Model for Osteosarcoma Utilizing Circulating CXCL10 and FLT3LG. Cancer. 2017;123(1):144-154. doi:10.1002/encr.30272.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161556/					
CTLA4	Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., . . . Mackall, C. L. (2016). Phase 1 Clinical Trial of Ipilimumab in Pediatric Patients With Advanced Solid Tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 22(6), 1364-1370. http://doi.org/10.1158/1078-0432.CCR-15-0491	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027962/					
GM-CSF	Aliper, A. M., Frieden-Korovkina, V. P., Buzdin, A., Roudnitsnev, S. A., & Zhavoronkov, A. (2014). A role for GM-CSF and GM-CSF in nonmyeloid cancers. Cancer Medicine, 3(4), 737-746. http://doi.org/10.1002/cam4.239	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303143/					
IDO1	Folgiero, V., Goffredo, B. M., Filippini, P., Masetti, R., Bonanno, G., Caruso, R., . . . Rutella, S. (2013). Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget, 5(8). doi:10.18632/oncotarget.1504	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039141/					
IFN-gamma	Reid GSD, Shan X, Coughlin CM, et al. Interferon-gamma dependent infiltration of human T cells into neuroblastoma tumors in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009;15(21):6602-6608. doi:10.1158/1078-0432.CCR-09-0829.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783077/					
IL-2	Capitini CM, Mackall CL, Wayne AS. Immune-based Therapeutics for Pediatric Cancer: Expert opinion on biological therapy. 2010;10(2):163-178. doi:10.1517/14712590903431022.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809005/					
LAG3	Birley, K., Chester, K., & Anderson, J. (2018). Antibody based therapy for childhood solid cancers. Current Opinion in Chemical Engineering, 19, 153-162. doi:10.1016/j.coche.2018.01.005	https://www.sciencedirect.com/science/article/pii/S2211339817300503					
OX40	Reuter, D., Staegle, M. S., Kuhnöl, C. D., & Föll, J. (2015). Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells. Frontiers in Oncology, 5, 242. http://doi.org/10.3389/fonc.2015.00242	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621427/					
PD-1/PD-L1	Chen, L., & Han, X. (2015). Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. The Journal of Clinical Investigation, 125(9), 3384-3391. http://doi.org/10.1172/JCI81011	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588362/	Allison M, Martin et al. PD-L1 expression in medulloblastoma: an evaluation by subgroup, Oncotarget (2018).	http://www.oncotarget.com/index.php/journal-oncotarget/page/article/view/8/pmh11-249518/pmh11-78227	Wagner LM, Adams VR. Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. OncoTargets and therapy. 2017;10:2097-2106. doi:10.2147/OTT.S124008.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396947/	
RELA	Dupain, C., Hartrampf, A. C., Urbinati, G., Georger, B., & Massaad-Massade, L. (2017). Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine. Molecular Therapy, Nucleic Acids, 6, 315-326. http://doi.org/10.1016/j.omtn.2017.01.005	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363511/					
RIG-I	Kaneda, Y. (2013). The RIG-I/MAVS signaling pathway in cancer cell-selective apoptosis. Oncoimmunology, 2(4), e23566. http://doi.org/10.4161/onci.23566	https://www.ncbi.nlm.nih.gov/pubmed/23734313					
STEAPl	Grunewald, T. G., Diebold, I., Esposto, I., Plehm, S., Hauer, K., Thiel, U., . . . Burdach, S. (2011). STEAP1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors. Molecular Cancer Research, 10(1), 52-65. doi:10.1158/1541-7786.mcr-11-0524	https://www.ncbi.nlm.nih.gov/pubmed/22080479					
STING	Lemos, H., Mohamed, E., Huang, L., Ou, R., Pacholczyk, G., Arbab, A. S., . . . Mellor, A. L. (2016). STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Research, 76(8), 2076-2081. http://doi.org/10.1158/0008-5472.CAN-15-1456	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873329/					
TIM3/TIM4	Williams, K. M., Grant, M., Ismail, M., Hoq, F., Martin-Mason, M., Hoover, J., . . . Ballard, C. (2017). Complete remissions post infusion of multiple tumor antigen-specific T cells for the treatment of high risk leukemia and lymphoma patients after HCT. Cytotherapy, 19(5). doi:10.1016/j.jcyt.2017.03.013	https://www.sciencedirect.com/science/article/pii/S1465324917304371					
VEGF	Glade Bender, J., Yamashiro, D. J., & Fox, E. (2011). Clinical Development of VEGF Signaling Pathway Inhibitors in Childhood Solid Tumors. The Oncologist, 16(11), 1614-1625. http://doi.org/10.1634/theoncologist.2011-0148	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233297/	Grill J, Massimino M, Bouffet E, Amedeo A, Azit A, McGowage G, Carotta A. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. DOI: 10.1200/JCO.2017.76.0611 Journal of Clinical Oncology 36, no. 10 (April 1 2018) 951-958	http://ascopubs.org/doi/abs/10.1200/JCO.2017.76.0611			
VEGFR	Kieran, M. W., Kalluri, R., & Cho, Y.-J. (2012). The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward. Cold Spring Harbor Perspectives in Medicine, 2(12), a006593. http://doi.org/10.1101/cshperspect.a006593	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC343071/					

Others	Target Symbol	Citation(1)	Link(1)	Citation(2)	Link(2)
		Barrett, D., Brown, V. I., Grupp, S. A., & Teachey, D. T. (2012). Targeting the PI3K-AKT/mTOR Signaling Axis in Children with Hematologic Malignancies. <i>Pediatric Drugs</i> , 14(5), 299-316. doi:10.1007/s0032602362	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214862/		
	AKT	Takagi, M., Yoshida, M., Nemoto, Y., Tamaichi, H., Tsuchida, R., Seki, M., ... Takita, J. (2017). Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor. <i>JNCI: Journal of the National Cancer Institute</i> , 109(11). doi:10.1093/jnci/djx062	https://academic.oup.com/jnci/article/109/11/djx062/4096548		
	ATM	Weber, A. M., & Ryan, A. J. (2015). ATM and ATR as therapeutic targets in cancer. <i>Pharmacology & Therapeutics</i> , 149, 124-138. doi:10.1016/j.pharmthera.2014.12.001	https://www.ncbi.nlm.nih.gov/pubmed/25512053	Nieto-Soler M, Morgado-Palacin I, Lafarga V, et al. Efficacy of ATR inhibitors as single agents in Ewing sarcoma. <i>Oncotarget</i> . 2016;7(37):58759-58767. doi:10.18632/oncotarget.11643.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312273/
	ATR	Roseman, C., Calmescu, A., Nunez, F. J., Mackay, A., Faisal-Saloun, J., Thomas, D., ... Castro, M. G. (2016). ATRX Loss Promotes Tumor Growth and Impairs Non-Homologous End Joining DNA Repair in Glioma. <i>Science Translational</i>	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381643/	Kroschmann C, Calmescu A-A, Nunez FJ, et al. ATRX Loss Promotes Tumor Growth and Impairs Non-Homologous End Joining DNA Repair in Glioma. <i>Science translational medicine</i> . 2016;8(326):326ra28. doi:10.1126/scitranslmed.aac8228.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381643/
	ATRX	Wetmore C, Boyett J, Li S, et al. ATRX is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. <i>Neuro-Oncology</i> . 2015;17(6):882-888. doi:10.1093/neuonc/nov017.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483126/		
	AURKA (Aurora kinase A)	Bavestias, V., & Linardopoulos, S. (2015). Aurora Kinase Inhibitors: Current Status and Outlook. <i>Frontiers in Oncology</i> , 5, 278. https://doi.org/10.3389/fonc.2015.00278	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680408/		
	AURKB (Aurora kinase B)	Huey, M. G., Minson, K. A., Eary, H. S., DeByckere, D., & Graham, D. K. (2016). Targeting the TAM Receptors in Leukemia. <i>Cancers</i> , 8(11), 101. http://doi.org/10.3390/cancers8110101	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126761/		
	AXL	Hahn, A. J., Guerra, R. M., Harvey, E. P., Bird, G. H., & Walensky, L. D. (2016). Selective Covalent Targeting of Anti-Apoptotic BCL-1 by Cysteine-Reactive Stapled Peptide Inhibitors. <i>Cell Chemical Biology</i> , 23(9), 1123-1134. http://doi.org/10.1016/j.chembiol.2016.07.022	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055752/		
	A1/BFL	Katz, S. G., Fisher, J. K., Correll, M., Bronson, R. T., Ligon, K. L., & Walensky, L. D. (2013). Brain and Testicular Tumors in Mice with Progesterone Cells Lacking BAX and BAK. <i>Oncogene</i> , 32(35), 4078-4085. http://doi.org/10.1038/ncr.2012.421	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529761/	Westhoff, M., Marschall, N., Grunert, M., Karpel-Massler, G., Buntack, S., & Debatin, K. (2018). Cell death-based treatment of childhood cancer. <i>Cell Death & Disease</i> , 9(2). doi:10.1038/s41419-017-0062-z	https://www.nature.com/articles/s41419-017-0062-z
	BAK	Kapoun, M., Choumranianou, D., Perdikogianni, C., Marimianaki, G., Kalmanti, M., & Stiakaki, E. (2013). Enhanced levels of the apoptotic BAX/BCL-2 ratio in children with acute lymphoblastic leukemia and high-risk features. <i>Genetics and Molecular Biology</i> , 36(1), 7-11. http://doi.org/10.1590/S1414-472013005000003	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615527/		
	BAX	Chaber, R., Fiszler-Maliszewska, L., Noworolska-Sauren, D., Kwasnicka, J., Wrobel, G., & Cypkiewicz, A. (2013). The BCL-2 Protein in Precursor B Acute Lymphoblastic Leukemia in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 35(3), 180-187. doi:10.1097/MPH.0b013e318286429b	https://www.ncbi.nlm.nih.gov/pubmed/23511489		
	BCL2 family members (Bcl-2, Bcl-XL, Mcl-1, A1/BFL, BAK, BAX)	Walhwa E, Nicolaides T (May 21, 2016) Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. <i>Cureus</i> 8(5): e620. http://doi.org/10.7759/cureus.620	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913737/	Hemel, T., Georgi, C., Schmidt, O., Calzadilla-Wack, J., Neff, F., Bach, T., ... Richter, G. H. (2015). Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. <i>Oncotarget</i> , 7(12). doi:10.18632/oncotarget.6385	https://medicatum.uib.tum.de/de/1298856/1298856.pdf
	BET bromodomain family	Liu, S., Tian, Z., Yin, F., Zhang, P., W., Y., Ding, X., ... Fan, M. (2009). Expression and Functional Roles of Smad1 and BMPRII in Glioma Development. <i>Cancer Investigation</i> , 27(7), 734-740. doi:10.1080/073790802620786	https://www.semanticscholar.org/lookup/Expression-and-functional-roles-of-smad1-and-bmprii-in-glioma-development?from=pdf&url=https://doi.org/10.1080/073790802620786		
	BMPR	Long, W., Yi, Y., Chen, S., Cao, Q., Zhao, W., & Liu, Q. (2017). Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Pharmacology</i> , 8. doi:10.3389/fphar.2017.00495	https://www.frontiersin.org/articles/10.3389/fphar.2017.00495/full	Abedin, S. M., Boddy, C. S., & Mumbly, H. G. (2016). BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. <i>Oncotargets and Therapy</i> , 9, 5943-5953. http://doi.org/10.2147/OTT.S100515	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047722/
	Btd1	Walhwa, E., & Nicolaides, T. (2016). Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. <i>Cureus</i> , 8(5), e620. http://doi.org/10.7759/cureus.620	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913737/	Stathis, A., & Bertoni, F. (2017). BET Proteins as Targets for Anticancer Treatment. <i>Cancer Discovery</i> , 8(1), 24-36. doi:10.1158/2159-8290.cd-17-0605	http://cancerdiscovery.aacrjournals.org/content/8/1/24.full
	Btd4	Hamilton, E., & Infante, J. R. (2016). Targeting CDK4/6 in patients with cancer. <i>Cancer Treatment Reviews</i> , 45, 129-138. doi:10.1016/j.ctrv.2016.03.002	https://www.deepdyve.com/lp/elsevier/targeting-cdk-4-6-in-patients-with-cancer-tsvBjBk02	Pikman Y, Alexe G, Roti G, et al. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. <i>Clinical cancer research: an official journal of the American Association for Cancer Research</i> . 2017;23(4):1012-1024. doi:10.1158/1078-0432.CCR-15-2869.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432118/
	CDK4/6	Prince, E. W., Balakrishnan, I., Shah, M., Mukkahy Levy, J. M., Griesinger, A. M., Alimova, L., ... V. Bhikar, R. (2016). Checkpoint kinase 1 expression in an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. <i>Oncotarget</i> , 7(35), 55881-55894. http://doi.org/10.18632/oncotarget.10692	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288228/	Lowrey, C. D., Vamsey, A. B., Drossus, M., Blosser, W., Fakon, B. L., Stewart, J., ... Stancato, L. F. (2017). The Checkpoint Kinase 1 Inhibitor Prexaerib Induces Regression of Preclinical Models of Human Neuroblastoma. <i>Clinical Cancer Research</i> , 23(15), 4354-4363. doi:10.1158/1078-0432.ccr-16-2876	http://clincancerres.aacrjournals.org/content/23/15/4354
	CHK1	Chen, Z., Wang, Z., Pang, J. C., Yu, Y., Biekerhahzi, S., Lu, J., ... Yang, J. (2016). Multiple CDK inhibitor diacetylols suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. <i>Scientific Reports</i> , 6, 29090. http://doi.org/10.1038/srep29090	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932496/		
	CDK2	Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., ... Gray, N. S. (2014). Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. <i>Nature</i> , 511(7511), 616-620. http://doi.org/10.1038/nature13393	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244910/		
	CDK7	Mereoni, N., Holsten, T., Mertins, J., Zhoghi, A., Johann, P., Kozl, M., ... Kertl, K. (2017). Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors. <i>Oncotarget</i> , 8(49), 84986-84995. http://doi.org/10.18632/oncotarget.18583	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689588/		
	CDK9	Richter, J., Ullah, K., Xu, P., Alschner, V., Blatz, A., Pfeifer, C., ... Knipschildt, U. (2014). Effects of altered expression and activity levels of CK1 δ and ϵ on tumor growth and survival of colorectal cancer patients. <i>International Journal of Cancer</i> , 136(12), 2799-2810. doi:10.1002/ijc.29346	https://onlinelibrary.wiley.com/doi/10.1002/ijc.29346	Buontempo, F., McCubrey, J. A., Orosi, E., Ruzzeo, M., Cappellini, A., Lonnati, A., ... Martelli, A. M. (2017). Therapeutic targeting of CK2 in acute and chronic leukemias. <i>Leukemia</i> , 32(1), 1-10. doi:10.1038/leu.2017.301	https://www.nature.com/articles/leu2017301
	CK1	Chau, M. M. J., Ortega, C. E., Sheikh, A., Lee, M., Abdul-Rassoul, H., Harshbom, K. L., & Dominguez, I. (2017). CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. <i>Pharmacokinetics</i> , 10(1), 18. http://doi.org/10.3390/ph10010018	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374432/		
	CK2 (casein kinase 2)	Mullighan, C. G., Zhang, J., Kopper, L. H., Lazar, S., Payne-Turner, D., Phillips, L. A., ... Downing, J. R. (2011). CREBBP mutations in relapsed acute lymphoblastic leukaemia. <i>Nature</i> , 471(7337), 235-239. http://doi.org/10.1038/nature09727	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076610/		
	CREBBP/EP300	Bobola, M. S. (2005). O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines. <i>Clinical Cancer Research</i> , 11(7), 2747-2755. doi:10.1158/1078-0432.ccr-04-2045	https://www.ncbi.nlm.nih.gov/pubmed/153814667		
	DNA (alkylators)	Dolman, M. E. M., van der Ploeg, I., Koster, J., Bato-Eya, L. T., Versteeg, R., Caron, H. N., & Molenaar, J. J. (2015). DNA-Dependent Protein Kinase As Molecular Target for Radioisotomization of Neuroblastoma Cells. <i>PLoS ONE</i> , 10(12), e0145744. http://doi.org/10.1371/journal.pone.0145744	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496738/	Becher, O. J., Peterson, K. M., Khutua, S., Santl, M. R., & MacDonald, T. J. (2008). IGF1R2 is Overexpressed by Pediatric Malignant Astrocytomas and Induces the Repair Enzyme DNA-PK. <i>Journal of Child Neurology</i> , 23(10), 1205-1213. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC674842/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC674842/
	DNA-PK				

DNMT (DNA methyl transferase)	Diede, S. J., Gaenther, J., Geng, L. N., Mahoney, S. E., Marotta, M., Olson, J. M., ... Tapscoft, S. J. (2009). DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. <i>Proceedings of the National Academy of Sciences</i> , 107(1), 234-239. doi:10.1073/pnas.0907606106 http://www.pnas.org/content/pnas/early/2009/11/20/107607606106.full.pdf .		
FAK	Waters, A. M., Stefan, L. L., Garner, E. F., Muthunayappa, S., Stewart, J. E., Mroczek-Musulman, E., & Beierle, E. A. (2016). Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells. <i>Translational Oncology</i> , 9(6), 263-273. http://doi.org/10.1016/j.tranon.2016.06.001 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925808/ .		
FOLR1 (folate receptor 1)	Oentas, R. J., Lee, D. W., & Mackall, C. (2012). Immunotherapy Targets in Pediatric Cancer. <i>Frontiers in Oncology</i> , 2, 3. http://doi.org/10.3389/fonc.2012.00003 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355849/ .	Liu H, Sun Q, Zhang M, et al. Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potential. <i>Oncotarget</i> . 2017;8(14):23048-23060. doi:10.18632/oncotarget.15480. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410284/ .	
GSK-3	Hu, Y., Gu, X., Li, R., Luo, Q., & Xu, Y. (2010). Glycogen synthase kinase-3 β inhibition induces nuclear factor- κ B-mediated apoptosis in pediatric acute lymphocytic leukemia cells. <i>Journal of Experimental & Clinical Cancer Research</i> , 29(1), 154. http://doi.org/10.1186/1759-9966-29-154 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902327/ .	Mills, C. N., Nowshheen, S., Bonner, J. A., & Yang, E. S. (2011). Emerging Roles of Glycogen Synthase Kinase 3 in the Treatment of Brain Tumors. <i>Frontiers in Molecular Neuroscience</i> , 4, 47. http://doi.org/10.3389/fnmol.2011.00047 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC323272/ .	Tang Q-L, Xie X-B, Wang J, et al. Glycogen Synthase Kinase-3 β , NF- κ B Signaling, and Tumorigenesis of Human Osteosarcoma. <i>PNCJ Journal of the National Cancer Institute</i> . 2012;104(10):749-763. doi:10.1093/pncj/djq210. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352831/ .
HDAC	West, A. C., & Johnstone, R. W. (2014). New and emerging HDAC inhibitors for cancer treatment. <i>The Journal of Clinical Investigation</i> , 124(1), 30-39. http://doi.org/10.1172/JCI69738 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871231/ .		
HIF1A	Cruzem, G. A., Reis, M. B., Silveira, V. S., Lima, R. C., Jr, C. G., Neder, L., ... Valera, E. T. (2018). HIF1A is Overexpressed in Medulloblastoma and its Inhibition Reduces Proliferation and Increases EPCAM and ATG16L1 Methylation. <i>Current Cancer Drug Targets</i> , 18(3), 287-294. doi:10.2174/15680096176661051562525 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428203/ .	Silveira VS, Freire BM, Borges KS, Andrade AF, Cruzem GA, Sabino JP, Glass ML, Yunes JA, Brandalise SR, Tone LG, Scrideli CA. Hypoxia-related gene expression profile in childhood acute lymphoblastic leukemia: prognostic implications. <i>Leuk Lymphoma</i> . 2014 Aug;55(8):1751-7. doi:10.1080/10428194.2013.858812. Epub 2014 Feb 14. https://www.ncbi.nlm.nih.gov/pubmed/24160851 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871231/ .	
Hippo pathway (YAP, TAZ, TEADs)	Almed, A. A., Mohamed, A. D., Gener, M. L. W., & Tashak, E. (2017). YAP and the Hippo pathway in pediatric cancer. <i>Molecular & Cellular Oncology</i> , 4(3), e1295127. http://doi.org/10.1080/23723556.2017.1295127 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462521/ .		
Hsp90	Li, W., Tsou, F., Saha, D., Bhatia, A., Chen, M., Multhoff, G., & Woodley, D. T. (2013). Extracellular Hsp90 (α 1b/90) as the Actual Target in Clinical Trials: Intentionally or Unintentionally. <i>International Review of Cell and Molecular Biology</i> , 303, 203-235. http://doi.org/10.1016/B978-0-12-407697-6.00005-2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073563/ .		
IAPs (inhibitor-of-apoptosis)	Tysner, J. W., Jemal, A. M., Thayer, M., Drake, B. J., & Chang, B. H. (2012). Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 26(4), 623-632. http://doi.org/10.1038/leu.2011.249 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364442/ .		
IGFR-1	BADR, M., HASSAN, T., TARIKINY, S. E., & METWALLY, W. (2010). Insulin-like growth factor-1 and childhood cancer risk. <i>Oncology Letters</i> , 1(6), 1055-1059. http://doi.org/10.3892/ol.2010.169 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412533/ .		
KDM4A	D'Oro, A., Tian, Q., Davidoff, A. M., & Yang, J. (2016). Histone demethylases and their roles in cancer epigenetics. <i>Journal of Medical Oncology and Therapeutics</i> , 1(2), 34-40. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279889/ .		
LSD1	Theisen, E. R., Pishas, K. I., Samd, R. S., & Lessnick, S. L. (2016). Therapeutic opportunities in Ewing sarcoma: EWS-FLI1 inhibition via LSD1 targeting. <i>Oncotarget</i> , 7(14), 17616-17630. http://doi.org/10.18632/oncotarget.7124 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951237/ .		
MCL1	Lundke, D. A., Niu, X., Pan, Y., Zhao, J., Liu, S., Edwards, H., ... Ge, Y. (2017). Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. <i>Signal Transduction and Targeted Therapy</i> , 2, 17012. doi:10.1038/s41395-017-112 https://www.nature.com/articles/sigtrans201712 .		
MCT1 (monocarboxylate transporter 1)	Noble, R. A., Bell, N., Blair, H., Sikka, A., Thomas, H., Phillips, N., ... Wedges, S. R. (2017). Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. <i>Haematologica</i> , 102(7), 1247-1257. http://doi.org/10.3324/haematol.2016.163030 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566036/ .		
MEK	Dupin, C., Hartmann, A. C., Ubbani, G., Georger, B., & Massaad-Abou, E. (2017). Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine. <i>Molecular Therapy. Nucleic Acids</i> , 6, 315-326. http://doi.org/10.1016/j.mtn.2017.01.005 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363511/ .	Jessen WJ, Miller SJ, Jossua E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. <i>The Journal of Clinical Investigation</i> . 2013;123(1):340-347. doi:10.1172/JCI60578. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533264/ .	
MIZ1	Yu, B. T., Wolf, E., Kawachi, D., Cebalgh, A., Reh, J. E., Finkelstein, D., ... Rossell, M. F. (2016). The interaction of Myc with Miz1 defines medulloblastoma subgroup identity. <i>Cancer Cell</i> , 29(1), 5-16. http://doi.org/10.1016/j.ccr.2015.12.003 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714043/ .		
MGMT	Saletta, F., Wadhwa, C., Ziegler, D. S., Marshall, G. M., Haber, M., Mccowage, G., ... Byrne, J. A. (2014). Molecular profiling of childhood cancer: Biomarkers and novel therapies. <i>BBA Clinical</i> , 1, 59-77. doi:10.1016/j.bbcli.2014.06.003 https://www.sciencedirect.com/science/article/pii/S2216647414000106 .		
MLL5	Gallo, M., Costinbo, F. J., Vanner, R. J., Guyden, T., Mack, S. C., Marston, A., ... Dicks, P. B. (2015). MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. <i>Cancer Cell</i> , 28(6), 715-729. doi:10.1016/j.ccr.2015.10.005 https://www.cell.com/cancer-cell/abstract/S1535-6108(15)00382-7 .		
MYST3 (MYST histone acetyltransferase (monocytic leukemia))	Andrade, F. G., Noronha, E. P., Baseggio, R. M., Fonseca, T. C. C., Freire, B. M. R., Querado-Malheiros, I. M., ... Pombino-de-Oliveira, M. S. (2016). Identification of the MYST3-CREBBP fusion gene in infants with acute myeloid leukemia and hemophagocytosis. <i>Revista Brasileira de Hematologia e Hemoterapia</i> , 38(4), 291-297. http://doi.org/10.1016/j.bjh.2016.06.005 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119666/ .		
NAMPT	Heske, C. M., Davis, M. I., Baumgart, J. T., Wilson, K., Gormally, M. V., Chen, L., ... Thomas, C. J. (2017). Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 23(25), 7301-7311. doi:10.1158/1078-0432.ccr-17-1121 https://www.ncbi.nlm.nih.gov/pubmed/28899971 .		
NEDD8 activating enzyme (NAE)	Bhatia, S., Pavlick, A. C., Boasberg, P., Thompson, J. A., Mulligan, G., Pickard, M. D., ... Hamid, O. (2016). A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924; MLN002) in patients with metastatic melanoma. <i>Investigational New Drugs</i> , 34, 439-449. http://doi.org/10.1007/s10637-016-0348-5 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919366/ .	Masoneri, S., & Zafra, G. (2015). Noddylation in glioblastomas. <i>Neuro-Oncology</i> , 17(10), 1305-1306. http://doi.org/10.1093/neuonc/nov165 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578592/ .	
PARP	Ricks, T. K., Chiu, H. J., Ison, G., Kim, G., McKee, A. E., Khatri, P., & Paudyal, R. (2015). Successes and Challenges of PARP Inhibitors in Cancer Therapy. <i>Frontiers in Oncology</i> , 5, 222. http://doi.org/10.3389/fonc.2015.00222 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604313/ .	Smith MA, Reynolds P, Kang MH, et al. Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. <i>Clinical cancer research: an official journal of the American Association for Cancer Research</i> . 2015;21(4):819-832. doi:10.1158/1078-0432.CCR-14-2572. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587665/ .	
PKC-1 (3-phosphoinositide-dependent protein kinase 1)	Velpula, K. K., Cuda, M. R., Sahu, K., Tuzymski, J., Awatramani, S., Bach, S. E., ... Tsang, A. J. (2017). Metabolic targeting of EGFR/PI3K/PDK1 axis in temozolomide resistant glioblastoma. <i>Oncotarget</i> , 8(22), 35639-35655. http://doi.org/10.18632/oncotarget.16767 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482605/ .		
PI3Kdelta	Smith, M. A., & Reaman, G. H. (2015). Remaining challenges in childhood cancer and newer targeted therapeutics. <i>Pediatric Clinics of North America</i> , 62(1), 301-312. http://doi.org/10.1016/j.pcl.2014.09.018 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336187/ .	Wang X, Zhang X, Li B, et al. Simultaneous targeting of PI3K α and PI3K δ -dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia. <i>Oncotarget</i> . 2014;5(21):10732-10744. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278406/ .	

Padli, S. K. R., Laveano, L. A., An, N., Pandey, R., Singh, N., Song, J. H., ... & Kraft, A. S. (2017). Targeting the PIM protein kinases for the treatment of T-cell acute lymphoblastic leukemia subset. *Oncotarget*, 8(18), 30199–30216. <http://doi.org/10.18632/oncotarget.16320> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444737/>

Huang, S. Y., & Yang, J.-Y. (2015). Targeting the Hedgehog Pathway in Pediatric Medulloblastoma. *Cancers*, 7(4), 2110–2123. <http://doi.org/10.3390/cancers7040880>

Kikuchi, K., Soondararajan, A., Zarabli, L. A., Weems, C. R., Nelson, L. D., Hampton, S. T., ... & Kelley, C. (2013). Protein Kinase C α as a Therapeutic Target in Alveolar Rhabdomyosarcoma. *Oncogene*, 32(3), 286–295. <http://doi.org/10.1038/onc.2012.46> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360112/>

Hartsink-Segers, S. A., Esalto, C., Clifford, S. C., Carra, H. N., Pieters, R., & Den Boer, M. L. (2012). Polo-Like Kinase 1 (PLK1) Inhibition Reduces Cell Proliferation and Induces Apoptosis in Childhood Acute Lymphoblastic Leukemia. *Blood*, 120(21), 3529. Accessed March 26, 2018. Retrieved from <http://www.bloodjournal.org/content/120/21/3529>. <http://www.bloodjournal.org/content/120/21/3529.full.pdf>

Jones, L., Carol, H., Evans, K., Richmond, J., Houghton, P. J., Smith, M. A., & Lock, R. B. (2016). A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. *Leukemia*, 30(11), 2133–2141. doi:10.1038/leu.2016.192 <https://www.nature.com/articles/leu2016192.pdf>

Cubedo, E., Martin, M., Jiang, X., Lossos, I. S., & Wright, K. L. (2011). PRDM1/Blimp1 Down-regulates Expression of Germinal Center Genes LMO2 and HGAL. *The FEBS Journal*, 278(17), 3065–3075. <http://doi.org/10.1111/j.1742-4658.2011.08227.x> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158840/>

Weidner, C. I., Lin, Q., Birkhofer, C., Gerstenmaier, U., Kaffie, A., Kirschner, M., ... & Wagner, W. (2016). DNA methylation in PRDM8 is indicative for dyskeratosis congenita. *Oncotarget*, 7(10), 10765–10772. <http://doi.org/10.18632/oncotarget.7458> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905437/>

Hofvander, J., Tayebwa, J., Nilsson, J., Magnusson, L., Brostig, O., Larsson, O., ... & Mertens, F. (2014). Recurrent PRDM10 Gene Fusions in Undifferentiated Pleomorphic Sarcoma. *Clinical Cancer Research*, 21(4), 864–869. doi:10.1158/1078-0432.ccr.14.2999 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2516889/>

Zhong, J., Cao, R., Zu, X., Hong, T., Yang, J., Liu, L., ... & Wen, C. (2011). Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma. *FEBS Journal*, 279(2), 316–335. doi:10.1111/j.1742-4658.2011.08426.x <http://dx.doi.org/10.1111/j.1742-4658.2011.08426.x>

Jin, Y., Zhou, J., Xu, F., Jin, B., Cui, L., Wang, Y., ... & Pan, J. (2016). Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. *The Journal of Clinical Investigation*, 126(10), 3961–3980. <http://doi.org/10.1172/JCI85239> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906815/>

Cloos, J., Roeten, M. S., Franke, N. E., Meerloo, J. V., Zweegman, S., Kaspers, G. J., & Jansen, G. (2017). (Immu)proteasomes as therapeutic target in acute leukemia. *Cancer and Metastasis Reviews*, 36(4), 599–615. doi:10.1007/s10555-017-9699-4 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC529071527/>

Lazo, J. (2018). Faculty of 1000 evaluation for In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. F1000 - Post-publication Peer Review of the Biomedical Literature. doi:10.34107/27810993.79354387 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924693/>

Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Simon, E. A., ... & Vakoc, C. R. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. *Nature*, 478(7370), 524–528. <http://doi.org/10.1038/nature10334> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328300/>

Zhang, R.-Y., Yu, Z.-H., Zeng, L., Zhang, S., Bai, Y., Miao, J., ... & Zhang, Z.-Y. (2016). SHP2 phosphatase as a novel therapeutic target for melanoma treatment. *Oncotarget*, 7(45), 73817–73829. <http://doi.org/10.18632/oncotarget.12074> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342016/>

Mazar, P. K., Reynold, N., Khatri, P., Jansen, P. W. T. C., Wilkinson, A., Liu, S., ... & Gozani, O. (2014). SMYD3 links lysine methylation of MAFK to Ras-driven cancer. *Nature*, 510(7504), 283–287. <http://doi.org/10.1038/nature13320> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122675/>

Khanna, G., Bushnell, D., & Odeh, M. S. (2008). Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors. *The Oncologist*, 13(4), 382–389. doi:10.1634/theoncologist.2007-0175 <http://theoncologist.alphamedpress.org/content/13/4/382.full>

Tyner, J. W., Jemal, A. M., Thayer, M., Druker, B. J., & Chang, B. H. (2012). Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. *Leukemia*, 26(4), 623–632. <http://doi.org/10.1038/leu.2011.249> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364443/>

D'Angelo, V., Iannotta, A., Ramaglia, M., Lombardi, A., Zanone, M. R., Desiderio, V., ... & Caraglia, M. (2015). EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches. *Journal of Experimental & Clinical Cancer Research*, 34(1), 83. <http://doi.org/10.1186/s13046-015-0191-0> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535295/>

St. Pierre, R., & Kadlec, C. (2017). Mammalian SWI/SNF Complexes in Cancer: Emerging Therapeutic Opportunities. *Current Opinion in Genetics & Development*, 42, 56–67. <http://doi.org/10.1016/j.cog.2017.02.004> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777332/>

Zhao, Z., Chen, L., Dawlaty, M. M., Pan, F., Weeks, O., Zhou, Y., ... & Xu, M. (2015). Combined loss of Tet1 and Tet2 promotes B-cell, but not myeloid malignancies in mice. *Cell Reports*, 13(8), 1692–1704. <http://doi.org/10.1016/j.celrep.2015.10.037> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764044/>

Hahn, K. (1999). Correction: Repression of the gene encoding the TGF- β type II receptor is a major target of the EWS-FLI1 oncogene. *Nature Genetics*, 23(4), 481–481. <https://www.ncbi.nlm.nih.gov/pubmed/10508520>

Tanyildiz HG, Kaygussuz G, Ural E, Tacyildiz N, Dincalan H, Yavuz G. The prognostic importance of TGF- β , TGF- β receptor, and fascin in childhood solid tumors. *Pediatric Hematology and Oncology* (2017)34, 238-253 <https://www.tandfonline.com/doi/full/10.1080/0888018.2017.1361838>

Recha, J. C. C., Cheng, C., Liu, W., Kishi, S., Das, S., Cook, E. H., ... & Relling, M. V. (2005). Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. *Blood*, 105(12), 4752–4758. <http://doi.org/10.1182/blood-2004-11-4544> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895000/>

Bredel, C., Lassmann, S., Pollock, J., Kovth, R., Hamilton, R., Volk, B., ... & Bredel, M. (2005). DNA topoisomerase II α and Her-2/neu gene dosages in pediatric malignant gliomas. *International Journal of Oncology*. doi:10.3892/ijo.26.5.1187 <https://www.ncbi.nlm.nih.gov/pubmed/15892708>

Kepp, L. M., & Katsanis, E. (2015). Targeted immunotherapy for pediatric solid tumors. *Oncimmunology*, 5(3). <https://www.tandfonline.com/doi/full/10.1080/21624020.2015.1087637>

Stanton, R. A., Gemert, K. M., Nettles, J. H., & Areija, R. (2011). Drugs That Target Dynamic Microtubules: A New Molecular Perspective. *Medicinal Research Reviews*, 31(3), 443–481. <http://doi.org/10.1002/med.20242> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155728/>

Enkin, J., Berzovskaya, A., Conway, A. S., Galinsky, I. A., Stone, R. M., Balogh, E., ... & Look, A. T. (2017). KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. *Leukemia*, 31(1), 143–150. <http://doi.org/10.1038/leu.2016.145> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220128/>

Sun, Y., Bell, J. L., Carter, D., Chieradi, S., Poulos, R. C., Milazzo, G., ... & Liu, T. (2015). WDR5 Supports an N-Myc Transcriptional Complex That Drives a Proliferative Gene Expression Signature in Neuroblastoma. *Cancer Research*, 75(23), 5143–5154. doi:10.1158/0008-5472.ccr.15-0423 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC426471359/>

Mueller, S., Hashizume, R., Yang, X., Kolkowitz, I., Okow, A.
K., Phillips, J., ... Haas-Kogan, D. A. (2014). Targeting Wee1
for the treatment of pediatric high-grade gliomas. *Neuro-
Oncology*, 19(3), 352–360.

<http://www.ncbi.nlm.nih.gov/pmc/article/PMC3924515>

<http://doi.org/10.1093/neuonc/nnt220>

WEE1

Automatic
Waivers

Target Symbol	Citation(1)	Link(1)	Citation(2)	Link(2)	Comment
AR	Sun, J., Wang, D., Guo, L., Fung, S., Wang, Y., & Xing, R. (2017). Androgen Receptor Regulates the Growth of Neuroblastoma Cells in vitro and in vivo. <i>Frontiers in Neuroscience</i> , 11, 116. http://doi.org/10.3389/fnins.2017.00116	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339338/			
ESR1	Lovén, J., Zinin, N., Wahlsström, T., Müller, I., Brodin, P., Fredlund, E., ... Henriksson, M. (2010). MYCN-regulated microRNAs repress estrogen receptor- α (ESR1) expression and neuronal differentiation in human neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 107(4), 1553–1558. http://doi.org/10.1073/pnas.0913517107	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824410/			
ESR2	Ashton, K., Prietto, A., Otton, G., Symonds, L., Meevoy, M., Attia, J., . . . Scott, R. (2009). Estrogen receptor polymorphisms and the risk of endometrial cancer. <i>BIOG: An International Journal of Obstetrics & Gynaecology</i> , 116(8), 1053–1061. doi:10.1111/j.1471-0528.2009.02185.x	https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/j.1471-0528.2009.02185.x			
GnRHR	Cheng, C. K., Chow, B. K., & Leung, P. C. (2003). An Activator Protein 1-Like Motif Mediates 17 β -Estradiol Repression of Gonadotropin-Releasing Hormone Receptor Promoter via an Estrogen Receptor α -Dependent Mechanism in Ovarian and Breast Cancer Cells. <i>Molecular Endocrinology</i> , 17(12), 2613–2629. doi:10.1210/me.2003-0217	https://academic.oup.com/mend/article/17/12/2613/2747437			
PSA/PSCA/PSMA	Matera, L. (2010). The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. <i>Cancer Treatment Reviews</i> , 36(2), 131–141. doi:10.1016/j.ctrv.2009.11.002	https://www.ncbi.nlm.nih.gov/pubmed/19954892	Cho, H., Cockle, P., Binder, J., Resini, W., White, P., & Jooss, K. Vaccine based immunotherapy regimen (VBIR) for the treatment of prostate cancer. <i>Cancer Res</i> , 76, (14 Supplement), LB-093-LB-093 (2016)		